Latest Remuneration News

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

Orion Equities reported a $1.33 million net profit for FY25, down 56% from the prior year, impacted by unrealised losses on key investments and a significant tax benefit reversal. The company’s portfolio remains anchored by stakes in Bentley Capital and Strike Resources.

Rent.com.au Limited reported a $3.69 million net loss for FY25 amid modest revenue growth, while securing significant funding to scale its RentBond® product and reshaping its leadership team.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

NTAW Holdings reported a slight revenue increase to $538 million for FY2025 but posted a significant net loss of $44 million, driven by a $39 million impairment charge and operational challenges including the loss of Dunlop distribution rights. The company is executing a business reset focusing on inventory, costs, and cash flow.

McMillan Shakespeare Limited reported steady FY25 growth with Normalised UNPATA of $103.2 million and an 8.3% dividend yield, underpinned by digital innovation and strategic investments.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.